This content is machine translated SGLT2 inhibitor convinces Dapagliflozin may score well in nephro- and cardioprotection Patients with diabetic nephropathy can now be effectively treated with SGLT2 inhibitors. They are also said to have cardioprotective effects. Dapagliflozin is now the first and only antidiabetic agent approved…
View Post 6 min This content is machine translated Chronic wounds Modern wound management is interdisciplinary and individualized Wound healing disorders are often a symptom of an underlying disease and manifest clinically in different ways. In addition to treatment of the underlying disease, local wound treatment is the…
View Post 4 min This content is machine translated Heart failure SGLT2 inhibitors – are the new preparations more than just good antidiabetic agents? SGLT2 inhibitors have been used successfully for some time in the treatment of diabetes mellitus. They are associated with effective blood glucose lowering through increased renal glucose excretion. But they…
View Post 4 min This content is machine translated GLP-1 receptor agonists Jack of all trades in the fight against type 2 diabetes GLP-1 receptor agonists (RA) have been used in the treatment of diabetic patients since 2005. For patients, their introduction was a milestone, as GLP-1 RAs have the great advantage of…
View Post 5 min This content is machine translated Type 2 diabetes mellitus Heart and kidney protected in different patient groups Approximately 40% of patients with type 2 diabetes mellitus (T2DM) develop diabetic kidney disease, which contributes to increased cardiovascular and mortality risk [1, 2]. This makes it all the more…
View Post 3 min This content is machine translated Type 1 diabetes Despite known cardiac risk, many patients are undertreated Cardiac problems such as coronary artery disease and heart failure are among the most common and dangerous complications of type 1 diabetes. The mortality risk is significantly increased. Although this…
View Post 4 min This content is machine translated Diabetes Cases Type 2 diabetes mellitus and marked obesity A 48-year-old, severely obese patient is diagnosed with full-blown metabolic syndrome during an operative evaluation of osteoarthritis of the upper ankle. His arterial hypertension, dyslipidemia, hyperuricemia, grade III obesity, and…
View Post 7 min This content is machine translated Diabetes Management Nephro- and cardioprotection as an interdisciplinary challenge Early detection and treatment of renal dysfunction and cardiovascular risk factors in type 2 diabetes mellitus is essential. Experts see a need for action in this area, especially with regard…
View Post 6 min This content is machine translated Sponsored Content Rybelsus® – Semaglutide as the world’s first and only oral GLP-1 analogue People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1) or its effect is reduced. Semaglutide, mimicking natural GLP-1, can compensate for this.1 It lowers blood glucose,…
View Post 1 min This content is machine translated Diabetes Cases Long-standing diabetic patient at high cardiovascular risk. A 65-year-old female patient with long-standing diabetes, hypertension, and hyperlipidemia comes to a new practice because of her primary care physician’s retirement. How should the new attending physician proceed? What…
View Post 3 min This content is machine translated Diabetes Therapy Do GLP-1 receptor agonists contribute to stroke prophylaxis? The risk of suffering a stroke is massively higher for diabetics than in the general population. New data suggest that dulaglutide reduces the risk of ischemic stroke in diabetic patients…
